5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Is there still a role for SPECT-CT in oncology in the PET-CT era?

      Nature reviews. Clinical oncology

      Animals, Humans, Multimodal Imaging, Neoplasms, diagnosis, therapy, Positron-Emission Tomography, Prognosis, Tomography, X-Ray Computed

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          For the evaluation of biological processes using radioisotopes, there are two competing technologies: single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Both are tomographic techniques that enable 3D localization and can be combined with CT for hybrid imaging. PET-CT has clear technical superiority including superior resolution, speed and quantitative capability. SPECT-CT currently has greater accessibility, lower cost and availability of a wider range of approved radiotracers. However, the past decade has seen dramatic growth in PET-CT with decreasing costs and development of an increasing array of PET tracers that can substitute existing SPECT applications. PET-CT is also changing the paradigm of imaging from lesion measurement to lesion characterization and target quantification, supporting a new era of personalized cancer therapy. The efficiency and cost savings associated with improved diagnosis and clinical decision-making provided by PET-CT make a cogent argument for it becoming the dominant molecular technique in oncology.

          Related collections

          Author and article information

          Journal
          23149896
          10.1038/nrclinonc.2012.188

          Comments

          Comment on this article